SEARCH:   Advanced

Blood, 1 September 2008, Vol. 112, No. 5, pp. 2139-2148. Prepublished online as a Blood First Edition Paper on May 15, 2008; DOI 10.1182/blood-2007-12-130021. This Article Full Text (PDF) All Versions of this Article: blood-2007-12-130021v1 112/5/2139    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kumpers, P. Articles by Ganser, A. Search for Related Content PubMed PubMed Citation Articles by Kumpers, P. Articles by Ganser, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 19, 2007 Accepted April 21, 2008 Angiopoietin-2 predicts disease-free survival after allogeneic stem-cell transplantation in patients with high-risk myeloid malignancies Philipp Kumpers, Christian Koenecke, Hartmut Hecker, Julian Hellpap, Rudiger Horn, Willem Verhagen, Stefanie Buchholz, Bernd Hertenstein, Jurgen Krauter, Matthias Eder, Sascha David, Gudrun Gohring, Hermann Haller, and Arnold Ganser* Center for Internal Medicine, Hannover Medical School, Hannover, Germany Instiute of Immunology, Hannover Medical School, Hannover, Germany Institute of Biometrics, Hannover Medical School, Hannover, Germany Institute of Virology, Hannover Medical School, Hannover, Germany Institute of Cellular and Molecular Pathology, Hannover Medical School, Hannover, Germany * Corresponding author; email: ganser.arnold{at}mh-hannover.de. Emerging data suggest a critical role for bone marrow (BM) angiogenesis in hematologic malignancies. The Angiopoietin/Tie ligand-receptor system is an essential regulator of this process. We evaluated whether circulating Angiopoietin-2 (Ang-2) is a predictor for the probability of disease-free survival (DFS) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk AML or MDS. Ang-2 was measured by ELISA in serum from 20 healthy controls and 90 patients with AML or MDS before initiation of combined cytoreduction and reduced-intensity conditioning for HSCT. Circulating Ang-2 was elevated in patients (median (range): 2.21 (0.18-48.84) ng/ml) compared to controls (0.87 (0.27-4.51) ng/ml; p<0.0001). Multivariate analyses confirmed the independent prognostic impact of Ang-2 (hazard ratio 2.46, 95% CI 1.27-4.76, p = 0.005), percentage of BM infiltration (HR 1.14, 95% CI 1.01-1.29, p = 0.033), and chemotherapy cycles prior to HSCT (HR 1.38, 95% CI 1.01-1.08, p = 0.048). Regression tree analysis detected optimal cut-off values for Ang-2, and recursively identified BM blasts and Ang-2 as the best predictors for DFS. As few predictors for DFS exist in the setting of allo-HSCT, Ang-2 may be used as a readily available biomarker to pre-estimate DFS and may open new perspectives for risk-adapted treatment of high-risk myeloid malignancies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P Kumpers, S David, M Haubitz, J Hellpap, R Horn, V Brocker, M Schiffer, H Haller, and T Witte The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus Ann Rheum Dis, October 1, 2009; 68(10): 1638 - 1643. [Abstract] [Full Text] [PDF] P. Kumpers, J. Hellpap, S. David, R. Horn, H. Leitolf, H. Haller, and M. Haubitz Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1845 - 1850. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020